PBMHealthcare · BiotechnologyPBM Stock Forecast: Psyence Biomedical Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 1 Aug 2026 — in the weakest quartile.
PBM stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Psyence Biomedical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Psyence Biomedical Ltd. — and when they’d sell — is the membership.
PBM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PBM, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PBM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Psyence Biomedical Ltd. (PBM) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 0.1×
- EV / EBITDA
- −0.7×
Cheaper than 73% of US stocks
Cheaper than 91% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −58.6%
- Return on assets
- −31.3%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PBM vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PBM appears on the weeks it earns a place.
Frequently asked questions about PBM stock
How does Ticker Nerd's model rank PBM?
As at 1 Aug 2026, Psyence Biomedical Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
What is the PBM stock forecast for 2030?
No analyst covering Psyence Biomedical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBM are extrapolating price history, which says nothing about the business.
What does Psyence Biomedical Ltd. do?
Psyence Biomedical Ltd. is a life science biotechnology company focused on developing botanical, nature-derived psilocybin-based psychedelic medicines for mental health disorders.
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. is a life science biotechnology company focused on developing botanical, nature-derived psilocybin-based psychedelic medicines for mental health disorders. It specializes in natural psilocybin products aimed at treating psychological trauma, anxiety, depression, adjustment disorder, post-traumatic stress disorder, stress, and grief, particularly in palliative care contexts for patients with incurable cancer diagnoses. The company's lead product candidate, PEX010, is a capsule containing naturally sourced psilocybin under Phase IIb clinical study for psilocybin-assisted psychotherapy. Psyence Biomedical Ltd. operates through an integrated platform encompassing in-house cultivation, manufacturing, and clinical development capabilities. It maintains partnerships, such as with iNGENu Pty Ltd, for advancing clinical trials. As a subsidiary of Psyence Group Inc., it positions itself as a pioneer in evidence-based psychedelic therapeutics targeting unmet needs in palliative care, addiction, and related mental health conditions. Founded in 2021 and headquartered in Toronto, Ontario, Canada, Psyence Biomedical Ltd. plays a role in the emerging field of psychedelic medicine within the biotechnology sector.
CEO Mr. Jody Aufrichtig · 12 employees · Canada · https://psyencebiomed.com